Regeneron

News

Regeneron seeks CheckMate in immuno-oncology play

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy pipeline and ending a barren spell for M&A in

News

FDA says no to AZ's Fasenra for nasal polyp indication

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketi

News

Dupixent falls short in phase 3 chronic spontaneous urticari...

Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic spontaneous urticaria (CSU) who don't respond to the only approved biologic treatment,

News

Genetic testing hopes to speed up drug development in rare eye diseases

Oxurion reports stronger data for diabetic eye disease drug

Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, in development for people with

News

Pfizer sees no way forward for Ionis-partnered vupanorsen

Pfizer has called time on its alliance with Ionis for cholesterol-lowering therapy vupanorsen, after a review of phase 2b data raised some questions about the antisense drug's efficacy and

News

Roche grabs FDA okay for would-be blockbuster eye drug faric...

The FDA has approved Roche's much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron's market leading drug Eylea.

Regeneron seeks CheckMate in immuno-oncology play

FDA says no to AZ's Fasenra for nasal polyp indication

Dupixent falls short in phase 3 chronic spontaneous urticari...

Oxurion reports stronger data for diabetic eye disease drug

Pfizer sees no way forward for Ionis-partnered vupanorsen

Roche grabs FDA okay for would-be blockbuster eye drug faric...

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Regeneron

Editor's Picks